title: Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug-drug interactions (DDIs) with improved adherence and tolerability.
authors.affiliation: Brighton and Sussex University Hospitals NHS Trust.
authors.forename: Larissa
authors.initials: L
authors.lastname: Mulka
authors.affiliation: Brighton and Sussex University Hospitals NHS Trust.
authors.forename: David
authors.initials: D
authors.lastname: Annandale
authors.affiliation: Brighton and Sussex University Hospitals NHS Trust.
authors.forename: Claire
authors.initials: C
authors.lastname: Richardson
authors.affiliation: Brighton and Sussex University Hospitals NHS Trust.
authors.forename: Martin
authors.initials: M
authors.lastname: Fisher
authors.affiliation: Brighton and Sussex University Hospitals NHS Trust.
authors.forename: Daniel
authors.initials: D
authors.lastname: Richardson
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000517:prevention & control; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D000068898:Raltegravir Potassium / Q000008:administration & dosage* / Q000009:adverse effects; D016903:Drug Monitoring
chemical_list: D019380:Anti-HIV Agents; D000068898:Raltegravir Potassium
keywords: ANTIRETROVIRAL THERAPY; COMPLIANCE; POSTEXPOSURE PROPHYLAXIS (HIV); PREVENTION